Actovegin vs Thymosin Beta-4

Overview

Actovegin and Thymosin Beta-4 are both pain management peptides, but they differ in mechanism, dosing, and regulatory status.

This page compares Actovegin and Thymosin Beta-4 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

Key differences

Primary use. Actovegin is categorised under Pain Management, while Thymosin Beta-4 falls under Pain Management. Because they target a similar goal, they are common alternatives to weigh against each other.

Regulatory status. Actovegin: not FDA-approved; treated as a research compound. Thymosin Beta-4: not FDA-approved; compounding permitted with a prescription as of April 2026.

Dosing. Actovegin is typically dosed at 5-10 ml (multiple weekly). Thymosin Beta-4 is typically dosed at 2-10 mg (weekly).

Can you stack them?

Some protocols combine peptides, but stacking Actovegin and Thymosin Beta-4 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between Actovegin and Thymosin Beta-4?

Actovegin and Thymosin Beta-4 are both pain management peptides, but they differ in mechanism, dosing, and regulatory status. Actovegin is not FDA-approved; generally classified as a research compound, whereas Thymosin Beta-4 is not FDA-approved; compounding permitted with a prescription (as of April 2026).

What is Actovegin used for?

Hypoxic pain and healing.

What is Thymosin Beta-4 used for?

Comprehensive tissue pain relief.

Can you take Actovegin and Thymosin Beta-4 together?

Some users combine peptides within a single protocol, but stacking Actovegin and Thymosin Beta-4 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.

Is Actovegin or Thymosin Beta-4 FDA-approved?

Actovegin is not FDA-approved; generally classified as a research compound. Thymosin Beta-4 is not FDA-approved; compounding permitted with a prescription (as of April 2026).